Another experimental study revealed that anti-IP-10 therapy attenuates murine acquired immunodeficiency syndrome (MAIDS) colitis through the blockade of Th1-cell trafficking and the reduction of IEC apoptosis [22]. This evidence concerns the gene CXCL10 and colitis.